Future Innovation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Future Innovation
Presidents of leading associations offer views on the industry's future.

Pharmaceutical Technology
Volume 36, Issue 7, pp. 142, 141

David Y. Mitchell, PhD, President, American Association of Pharmaceutical Scientists (AAPS)



"The pharmaceutical sciences are moving towards a new era and continue to adapt, evolve, and thrive despite some well-documented growing pains. In the US and EU, there has been a pronounced shift to produce a leaner R&D process in large pharma, with a move in workforce towards smaller companies, CROs, CMOs, and biotechnology startups. Whereas, in Asia Pacific, pharma is expanding their footprint with clinical trials and new manufacturing sites, new government and private industry technical centers to promote basic science research, and a goal of becoming one of the top research and marketing regions of the world.

"The industry now not only looks internally for new drug-development leads, but also towards smaller pharma, biotechnology companies, and academic institutions, with their focused research programs and their quick and nimble operations, to bring forth the potential medicines of tomorrow. Further, the pharma industry is expanding globally to leverage new markets and low-cost alternatives for drug development.

"AAPS would like to congratulate Pharmaceutical Technology on its 35th anniversary. We're looking forward to continuing our strong partnership as we navigate these changes that will impact of our industry for the next 35 years."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here